Et al Phillip Frost MD - 09 Jan 2026 Form 4 Insider Report for Cocrystal Pharma, Inc. (COCP)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: COCP
Reported as of: 09 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Jan 2026, 16:10:05 UTC
Prior SEC filing: 02 Jan 2026
Next SEC filing: 09 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Phillip Frost, MD ET AL

Key filing fact

Et al Phillip Frost MD filed Form 4 for Cocrystal Pharma, Inc. (COCP) on 13 Jan 2026.

Key facts

This page summarizes Et al Phillip Frost MD's Form 4 filing for Cocrystal Pharma, Inc. (COCP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 13 Jan 2026, 16:10.

Change

Previous filing in this sequence was filed on 02 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0000898860 Primary reporting owner

FROST PHILLIP MD ET AL

Relationship: Director, 10%+ Owner
Address: 4400 BISCAYNE BLVD, MIAMI
Signature: /s/ Phillip Frost, MD ET AL
Signature date: 13 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

COCP transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value: $0
Shares: +24,615
Change %
Price: $0.000000
Shares after: 24,615
Date: 09 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 24,615
Exercise price: $1.10
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as a director of the Issuer on each applicable vesting date.

SEC remarks

This Form 4 does not include any of the securities owned directly by OPKO Health, Inc., a company of which Dr. Frost is the Chairman of the Board and Chief Executive Officer, concerning the securities of which Dr. Frost does not hold voting and investment control. Dr. Frost disclaims beneficial ownership of the securities held by OPKO Health, Inc. except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that Dr. Frost is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.